Citations

Clear

1792 citation(s) found for "Stephanie".

Thirty-Day Outcomes Following Pediatric Cranioplasty: An Analysis of 249 Patients
Gharavi, Aidin , Patel, Hiteshi, Polites, Stephanie F. , Ahn, Edward S. , Gharavi, Aidin , Habermann, Elizabeth B. , Mardini, Samir , Gibreel, Waleed

Mayo Clinic

Journal of Craniofacial Surgery | August 22, 2025 | Volume: 36 | Issue: 7 | Pages: 2396-2400

10.1097/scs.0000000000011759 | PMID 40845319 Get It

Surgical outcomes and perioperative factors associated with pediatric cranioplasty remain incompletely understood. The authors queried the National Surgical Quality Improvement Program-Pediatric (NSQIP-P) database to evaluate outcomes and intraoperative/postoperative blood transfusions in patients undergoing cranioplasty between 2019 and 2023. A total of 249 patients (mean age 9.1 ± 5.4 y) were included. Most cranioplasties (70.7%) utilized alloplastic materials compared with autologous. Blood transfusion was required in 24.1% of cases, predominantly on the day of surgery (86.7%). Multivariable analysis identified age (OR: 0.86 per year, 95% CI: 0.80–0.93, P < 0.001) and cranioplasty size >5 cm (versus ≤5 cm) (OR: 2.10, 95% CI: 1.01–4.50, P = 0.049) as predictors of transfusion. The 30-day unplanned readmission rate was 5.3% at a mean of 14.6 ± 7.9 days from surgery, most commonly for a surgical site infection (33.0%). The 30-day unplanned reoperation rate was 2.9%, at a mean of 10.2 ± 5.6 days. Autologous cranioplasty was not associated with higher odds of readmission (OR: 0.79, 95% CI: 0.25–2.13, P = 0.66) or reoperation (OR: 5.04, 95% CI: 0.96–36.99, P = 0.07) compared with alloplastic cranioplasty. Rates of readmission and reoperation following pediatric cranioplasty are comparable to other complex craniofacial procedures. Younger age and larger cranioplasty size are associated with higher rates of blood transfusion. Our results show that autologous reconstruction is not associated with higher short-term complication rates compared with alloplastic reconstruction, although future studies are still needed to further the understanding of the optimal cranioplasty material.
Endometrial Cancer: A Daily Clinical Practice Guide for Radiologists
McPhedran, Rachel , Aineseder, Martina , Chacón, Carolina, Causa Andrieu, Pamela , McPhedran, Rachel L, Andrieu, Pamela Causa , Avesani, Giacomo , Quesada, Stanislas , Rigiroli, Francesca , Kido, Aki , Nougaret, Stéphanie

Mayo Clinic

Magnetic Resonance in Medical Sciences | August 19, 2025 | Volume: 24 | Issue: 3 | Pages: 387-402

10.2463/mrms.rev.2025-0004 | PMID 40835435 Get It

Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer Measure
Sampathkumar, Yashasvini , Rogak, Lauren , Ginos, Brenda, Kantor, Elizabeth D. , Bennett, Antonia V. , Santos, Yolanda Martínez , Suarez, Jennifer , López, Camila , Narang, Bharat , Killoran, Kathleen, Spears, Patricia A. , Wolf, Anna , Weiss, Anna , Basch, Ethan , Gany, Francesca , Blinder, Victoria , Mazza, Gina L , Rogak, Lauren J , Ginos, Brenda F, Kantor, Elizabeth D , Bennett, Antonia V , Spears, Patricia A , Wheeler, Stephanie B , Reeve, Bryce B. , Basch, Ethan , Gany, Francesca , Blinder, Victoria S , Voils, Corrine I. , Santos, Yulianny De Los, González, Javier , Killoran, Kathleen, Wolf, Anna P., Wheeler, Stephanie B.

Mayo Clinic

JCO Oncology Practice | August 19, 2025 | Volume: 22 | Issue: 6 | Pages: 1030-1039

10.1200/op-25-00477 | PMID 40829100 Get It

PURPOSE Patients with cancer take different types of medications with varying schedules and settings. They are also sometimes instructed to stop medications due to toxicity. To measure self-reported nonadherence in this heterogeneous population, we modified and evaluated a measure originally developed to assess nonadherence to daily oral antihypertensives, the Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence). METHODS The measure was refined in an iterative process incorporating feedback from patient investigators and participant interviews in English and Spanish. Branching logic was added for participant selection of medication administration setting: (1) only home, (2) only clinic, or (3) partly home/partly clinic. Participants reported their adherence to medications taken over a setting-specific reference period (1 week for home, 1 month for clinic medications). Participants who missed medications then reported on reasons for nonadherence. Adherence was dichotomized for analysis (complete adherence v any nonadherence). For participants who received clinic-administered medications, concordance between chart-abstracted and self-reported adherence was evaluated. RESULTS Seventy-three participants completed the measure (68% English; 32% Spanish; 86% female; 44% age ≥60 years). The majority had breast cancer; 64% had metastatic disease. Twenty-six percent (15/58) of participants who received medication in clinic and 24% (11/46) of those who took medication at home reported nonadherence. Participants felt able to respond accurately to both reference periods and perceived all reasons for nonadherence to be relevant. Among participants who completed the final version of the measure for clinic-administered medication, 96% (26/27) accurately reported their adherence compared with chart-abstracted data. CONCLUSION Our results support the validity of the DOSE-Nonadherence-Cancer for assessing cancer treatment nonadherence. This measure can be used to assess nonadherence in patients with cancer receiving a broad array of systemic therapies.
Advances in Kidney Transplant, Machine Perfusion, and Viability Markers
Ohara, Stephanie , Chávez‐Villa, Mariana , Mao, Shennen A. , Clendenon, Jacob , Heimbach, Julie, Ryan, Randi , Kodali, Lavanya, Nguyen, Michelle C., Nateras-Nunez, Rafael, Jadlowiec, Caroline C. , Jadlowiec, Caroline , Mao, Shennen A , Ohara, Stephanie Y , Ryan, Randi J. , Clendenon, Jacob N. , Chavez-Villa, Mariana , Heimbach, Julie, Kodali, Lavanya, Nguyen, Michelle C., Nateras-Nunez, Rafael

Mayo Clinic

Kidney and Dialysis | August 14, 2025 | Volume: 5 | Issue: 3 | Pages: 37

10.3390/kidneydial5030037 Get It

Despite improvements in kidney transplantation rates, the shortage of donor kidneys remains a critical issue, exacerbated by non-utilization of recovered kidneys due to quality concerns, necessitating advancements in perfusion methods to enhance graft outcomes and usage. Although static cold storage remains the default standard for kidney preservation, newer methods like hypothermic machine perfusion have shown improved outcomes, including reduced delayed graft function and better survival rates. Hypothermic oxygenated machine perfusion and normothermic machine perfusion offer some potential clinical benefits but studies to date have demonstrated mixed results. In the United States, LifePort and the XVIVO’s Kidney Assist Transport are the most popular hypothermic perfusion devices, with NMP devices mostly in trials. Combining perfusion with biomarkers such as mitochondrial flavin mononucleotide, neutrophil gelatinase-associated lipocalin, and osteopontin shows promise in assessing kidney viability and predicting post-transplant outcomes, though further research is also needed. Emphasis on repair biomarkers, such as uromodulin and osteopontin, aims to better predict graft outcomes and develop new therapies. While notable advancements have been made in the use of machine perfusion and viability testing for liver transplantation, additional research with larger sample sizes is essential to substantiate these results and enhance kidney transplantation outcomes.
Understanding the sexual concerns of older women presenting for care to women’s health clinics: a cross-sectional study
Karam, J H, Shufelt, Chrisandra , Kingsberg, Sheryl A. , Cole, Kristin , Kapoor, Ekta , Mara, Kristin C. , Winham, Stacey, Mara, Kristin C , Shufelt, Chrisandra L , Karam, Jana, Winham, Stacey J. , Kling, Juliana M. , Faubion, Stephanie S.

Mayo Clinic

Menopause | August 12, 2025 | Volume: 32 | Issue: 12 | Pages: 1095-1102

10.1097/gme.0000000000002617 | PMID 40794483 Get It

Objective: To compare the prevalence of female sexual dysfunction (FSD) and distress between sexually active midlife women (50-64 y) and older women (65+ y) presenting for care at women’s health clinics at a tertiary care center. Methods: This cross-sectional study included women aged 50 and above who received care at Mayo Clinic women’s health clinics in Rochester, MN; Scottsdale, AZ; and Jacksonville, FL, between May 1, 2015, and August 31, 2022. Sexual function and distress were compared between midlife and older women using the Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), and self-reported sexual health concerns. Results: Among 3,465 sexually active women, older women were less likely to report loss of sexual desire (33.4% vs. 47.6%; P <0.001) and reduced genital sensation (13.0% vs. 16.9%; P =0.024) compared with midlife women. There were no significant differences for vaginal dryness, painful intercourse, or arousal/orgasm difficulties. FSFI scores were higher in older women for desire (3.0 vs. 2.4; P <0.001) and lubrication (3.9 vs. 3.6; P <0.001). While total FSFI scores were similar between older and midlife women (21.2 vs. 22.2; P =0.11), sexually related distress was lower in older women compared with midlife women (13.0 vs. 15.0; P =0.015). The prevalence of FSD (defined as FSFI score ≤26.55 and FSDS-R score ≥11) was similar between groups (51.8% vs. 56.2%; P =0.056). Conclusions: Older women experienced FSD at similar rates as midlife women but reported less sexual distress, potentially reflecting lower expectations regarding sexual function. Addressing sexual health concerns in older women may enhance quality of life.
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Mékinian, A. , Georgin‐Lavaille, Sophie, Savic, Sinisa , Koster, Matthew J. , Comont, Thibault , Heilblig, Mael, Aróstegui, Juan I. , Bosco, Annmarie , Cargo, Catherine , Cattaneo, Chiara , Chasset, François , Coelho, Henrique , Ducharme‐Bénard, Stéphanie , Frassi, Micol, Hakobyan, Yervand , Jurcuț, Ciprian , Kirino, Yohei , Kunimoto, Hiroyoshi , Madigan, Lauren M. , Moráis, Sara , Sockel, Katja , Patnaik, Mrinal M. , Regadas, Luísa, Robin, Marie , Rutgers, Abraham , Salvarani, Carlo , Sammel, Anthony M. , Sujobert, Pierre , Tomelleri, Alessandro , Vandergheynst, Frédéric , Vieira, Romana, Viswanatha, David S., Diral, Elisa , Terrier, Benjamin , Fenaux, Pierre, Grayson, Peter C. , Beck, David B. , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological, Mékinian, Arsène , Koster, Matthew J , Bourguiba, Rim , Campochiaro, Corrado , Crisafulli, Francesca , Gurnari, Carmelo , Jamilloux, Yvan , Kirino, Yohei , Marvisi, Chiara , Milchert, Marcin , Rutgers, Abraham , Salvarani, Carlo , Tomelleri, Alessandro , Urbanski, Geoffrey , Terrier, Benjamin , Grayson, Peter C , Beck, David B , Robin, Marie , Savic, Sinisa , Georgin‐Lavialle, Sophie , Ferrada, Marcela A. , Kosmider, Olivier , Calvo, Katherine R. , Campochiaro, Corrado , Faria, Raquel , Franceschini, Franco , Groarke, Emma M , Gurnari, Carmelo , Kulasekararaj, Austin , Mann, H. , Marvisi, Chiara , Milchert, Marcin , Muratore, Francesco , Nakajima, Hideaki , Seebach, Jörg Dieter , Więsik–Szewczyk, Ewa , Patel, Bhavisha A. , Fenaux, Pierre , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological

Mayo Clinic

Arthritis & Rheumatology | August 11, 2025 | Volume: 78 | Issue: 3 | Pages: 509-522

10.1002/art.43287 | PMID 40787890 Get It

Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.
Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
Association of hormone therapy and outcomes in COVID-19
Kuhle, Carol L. , Wahner‐Roedler, Dietlind L. , Sauver, Jennifer St., Schroeder, Darrell R. , Kapoor, Ekta , Mannion, Samantha , Nordhues, Hannah C. , Croghan, Ivana T. , Schroeder, Darrell , Fischer, Karen M. , St Sauver, Jennifer L , Kapoor, Ekta , Faubion, Stephanie S.

Mayo Clinic

Menopause | August 5, 2025 | Volume: 32 | Issue: 11 | Pages: 1002-1007

10.1097/gme.0000000000002598 | PMID 40763256 Get It

Objectives: To investigate the association between hormone therapy use and severe outcomes due to COVID-19 in perimenopausal and postmenopausal women. Methods: Using the Rochester Epidemiology Project, we retrospectively searched for the records of women aged 40-65 years who had a documented case of COVID-19 between March 12 and September 29, 2020. We further identified those who were perimenopausal or postmenopausal. The rates of emergency department visits, hospitalizations, and deaths were compared by hormone therapy use. Logistic regression models were used to assess the odds of the combined outcome based on hormone therapy use. Results: Among the 689 patients included in this study, the median age was 56 years, and 77.5% were White. Compared with patients currently using hormone therapy, those with past/never use of hormone therapy were significantly older, had more risk factors for severe COVID-19, and had a higher incidence of diabetes. A total of 102 emergency department visits/hospitalizations/deaths occurred among both groups. Participants with current hormone therapy use had similar rates and risk of emergency department/hospitalization/death outcomes as those without hormone therapy, even after adjusting for age and severe COVID-19 risk factors. Conclusions: Severe COVID-19 outcomes were not significantly different between women with current versus past/never use of hormone therapy. Our study adds to the data suggesting no harm with hormone therapy use in women with severe symptoms of COVID-19.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel, Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 284-291

10.6004/jnccn.2025.0038 | PMID 40763788 Get It

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.
Pediatric cervical spine clearance: a 10-year evaluation of X-ray in evaluable patients at a level 1 pediatric trauma center
Starr, William , Iantorno, Stephanie E. , Wang, Jing , Iyer, Rajiv R. , Smith, Karch, McNamara, Natalya , Larsen, Kezlyn, Fenton, Stephen J. , Swendiman, Robert A. , Eldredge, Richard, Russell, Katie , Wang, Jing, Eldredge, R Scott , Russell, Katie W.

Mayo Clinic

Trauma Surgery & Acute Care Open | August 3, 2025 | Volume: 10 | Issue: 3 | Pages: e001539

10.1136/tsaco-2024-001539 | PMID 40761845 Get It

Objectives Cervical spine (c-spine) X-ray (XR) remains an important tool for pediatric trauma patients. XR is a low radiation alternative to multidetector CT (MDCT). Our primary aims were to analyze the sensitivity of a negative c-spine XR and to analyze what factors lead to additional imaging after a negative c-spine XR. Methods A retrospective cohort study was conducted at a level 1 pediatric trauma center from 2012 to 2021. We compared the group with negative c-spine XR and no additional imaging to the group with negative c-spine XR followed by additional c-spine MDCT and/or MRI. Results There were 2,081 negative XRs and 1,974 (95%) had their c-spines cleared without additional imaging. No patient required an operation for a clinically significant c-spine injury in this group, and we consider this no missed injuries. The remaining 108 patients had additional c-spine imaging after negative c-spine XR for c-spine clearance (24 MDCT, 76 MRI, 8 MDCT and MRI). Indications for additional c-spine imaging were pain (48.1%), Glasgow Coma Scale (GCS) score ≤14 (43.5%), and paresthesia (8.3%). Patients who received additional imaging were more likely to have a GCS score ≤12 (25.4% vs 4.1%), Injury Severity Score >15 (21.9% vs 8.1%), Level 1 Trauma activation (21% vs 5%), Abbreviated Injury Scale head score of 4 or 5 (29% vs 5%), be intubated (30% vs 2%), and have non-accidental trauma as their mechanism of injury (20% vs 1%) (p value<0.0001, for all). Five patients who received additional imaging were treated with a cervical collar, but no operative intervention. Conclusions In this cohort, screening XR had a sensitivity of 100% for clinically significant c-spine injuries. GCS was the most significant predictor of obtaining additional imaging. A negative XR combined with a normal physical examination in an evaluable pediatric patient is a safe way of clearing the c-spine. Level of evidence Study contains level III evidence.